1 Home Furnishings Stock Set to Rally Hard?
Mortgage rates remain near multi-decade highs, and existing home sales are still down about 30% compared to pre-pandemic levels. That slowdown has created a ripple effect, dragging down everything tied to housing, from builders to brokers to the companies selling furniture and décor.
One name that stands out in this group is RH.
» Read more about: 1 Home Furnishings Stock Set to Rally Hard? »
Read More
Could This Tiny Nuclear Company Power the Future of Data and AI?
NuScale Power (NYSE: SMR) isn’t your typical energy company. It’s a trailblazing player in nuclear innovation, aiming to rewrite how the world generates clean, consistent power. Rather than betting on sprawling, billion-dollar nuclear facilities, NuScale is going small, really small, with its modular reactors, designed to be trucked in and switched on as needed.
It sounds futuristic.
» Read more about: Could This Tiny Nuclear Company Power the Future of Data and AI? »
Read More
2 Energy Giants Practically Mint Cash
Unlike upstream drillers who live by the barrel, Energy Transfer and Kinder Morgan quietly rake in stable cash flows by simply moving, storing, and processing hydrocarbons. Their businesses are mostly fee-based, and that makes them unusually resilient, especially in a market that punishes volatility.
Let’s dig into why these two midstream powerhouses are in a class of their own when it comes to cash generation,
» Read more about: 2 Energy Giants Practically Mint Cash »
Read More
Will This Titan Be The Biggest Winner of the AI Revolution?
For decades, Oracle was considered something of a tech stalwart, respected, reliable, and, frankly, a little boring. Known for its dominance in database management, Oracle’s steady performance made it a favorite among conservative investors, but rarely the centerpiece of high-growth conversations.
That’s changing, and fast. Thanks to a massive shift in enterprise computing driven by artificial intelligence Oracle is no longer just a database company.
» Read more about: Will This Titan Be The Biggest Winner of the AI Revolution? »
Read More
Is Figma’s Stock a Falling Knife or a Hidden Bargain?
It didn’t take long for Figma to go from Wall Street’s darling to one of its biggest disappointments.
After a blockbuster debut this summer, the stock has been sliding steadily, leaving many early investors deep in the red. But is the sell-off a warning sign, or has the market simply overreacted?
Key Points
-
Figma grew revenue 41% year over year and turned a $178 million cash burn into $62.5 million in positive operating cash flow,
» Read more about: Is Figma’s Stock a Falling Knife or a Hidden Bargain? »
Read MoreThe Ivy
Why Nvidia Could Still Be in the Early Innings of a Historic Run
Nvidia didn’t just ride the AI wave, it built the surfboard thanks to the graphics processing unit that evolved from powering video games to becoming the computational engine of the AI revolution.
Today, roughly 92% of all AI data center processing runs on Nvidia chips, according to IoT Analytics. That kind of market share is virtually unheard of in hardware.
» Read more about: Why Nvidia Could Still Be in the Early Innings of a Historic Run »
Read MoreThe Spotlight
Could Lemonade’s AI Insurance Engine Turn $1 Billion Into $10 Billion
After months of market jitters, earnings season has brought a wave of upbeat results, and stocks tied to improving outlooks are rallying hard.
Many investors who sat on the sidelines during the downturn are now realizing they may have missed some exceptional entry points.
But the best opportunities are about finding businesses with a runway long enough to turn today’s price into tomorrow’s fortune.
» Read more about: Could Lemonade’s AI Insurance Engine Turn $1 Billion Into $10 Billion »
Read MoreThe Daily
CRISPR Therapeutics Options Trading: A Deep Dive into Market Sentiment
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of …
» Read more about: CRISPR Therapeutics Options Trading: A Deep Dive into Market Sentiment »